	US 12,239,732 B2
	Anti-CD37 immunoconjugate and anti-CD20 antibody combinations
Angela Romanelli, Lexington, MA (US); Rodrigo R. Ruiz-Soto, Boston, MA (US); Jose Ponte, Weymouth, MA (US); Jutta Deckert, Lexington, MA (US); and Jan Pinkas, Belmont, MA (US)
Assigned to DEBIOPHARM INTERNATIONAL, S.A., Lausanne (CH)
Filed by Debiopharm International, S.A., Lausanne (CH)
Filed on Jul. 25, 2022, as Appl. No. 17/814,728.
Application 17/814,728 is a continuation of application No. 16/170,160, filed on Oct. 25, 2018, granted, now 11,395,796.
Application 16/170,160 is a continuation of application No. 15/171,732, filed on Jun. 2, 2016, abandoned.
Claims priority of provisional application 62/263,449, filed on Dec. 4, 2015.
Claims priority of provisional application 62/172,672, filed on Jun. 8, 2015.
Prior Publication US 2023/0190638 A1, Jun. 22, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 47/68 (2017.01); A61P 35/02 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)

CPC A61K 9/0019 (2013.01) [A61K 47/6801 (2017.08); A61K 47/68033 (2023.08); A61K 47/6849 (2017.08); A61K 47/6867 (2017.08); A61P 35/02 (2018.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01)]

12 Claims

1. A method for treating a human patient having a B-cell cancer comprising administering to said patient in need thereof (i) an immunoconjugate that binds to CD37 comprising a DM1 maytansinoid, a linker, and an antibody that binds to CD37 comprising the variable heavy chain sequence set forth in SEQ ID NO: 12 and the variable light chain sequence set forth in SEQ ID NO: 15; and (ii) rituximab, wherein said immunoconjugate that binds to CD37 is administered at a dose of 0.7 mg/kg once every three weeks and wherein the rituximab is administered at a dose of about 375 mg/m²on week 1, day 1 of a three week schedule.